MRK•benzinga•October 31, 2024 at 10:40 AM

Merck Expects 2024 Adjusted EPS Of $7.72-$7.77 Compared To Prior Guidance Of $$7.94-$8.04 And Consensus Of $7.74, Outlook Reflects a Net Negative Impact of $0.24/Share Related to Business Development Transactions With Curon Biopharmaceutical and Daiichi S

No summary available.

Read the full article from the original source for complete details and context.

Article published on October 31, 2024 by benzinga